These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20215552)

  • 1. Phase I clinical trials: overcoming barriers.
    Bates SE
    Clin Cancer Res; 2010 Mar; 16(6):1709. PubMed ID: 20215552
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
    Di Maio M; Daniele B; Gallo C; Perrone F
    J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
    [No Abstract]   [Full Text] [Related]  

  • 3. Better protection for human subjects is outcome of very early clinical trials.
    Maloney DM
    Hum Res Rep; 2006 May; 21(5):1-2. PubMed ID: 16832915
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase I cancer trials. A collusion of misunderstanding.
    Miller M
    Hastings Cent Rep; 2000; 30(4):34-43. PubMed ID: 10971892
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical development plan: N-Acetyl-l-cysteine.
    Kelloff GJ; Crowell JA; Boone CW; Steele VE; Lubet RA; Greenwald P; Alberts DS; Covey JM; Doody LA; Knapp GG
    J Cell Biochem Suppl; 1994; 20():63-73. PubMed ID: 7616754
    [No Abstract]   [Full Text] [Related]  

  • 6. Referral and decision making among advanced cancer patients participating in Phase I trials at a single institution.
    Gordon EJ; Daugherty CK
    J Clin Ethics; 2001; 12(1):31-8. PubMed ID: 11428154
    [No Abstract]   [Full Text] [Related]  

  • 7. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM; Boerner SA; Seymour L
    Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palliative care: a supportive adjunct to pediatric phase I clinical trials for anticancer agents?
    Ulrich CM; Grady C; Wendler D
    Pediatrics; 2004 Sep; 114(3):852-5. PubMed ID: 15342863
    [No Abstract]   [Full Text] [Related]  

  • 9. [Continual reassessment method (CRM)].
    Ishizuka N
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS.
    Estey EH
    Ann Hematol; 2004; 83 Suppl 1():S94-6. PubMed ID: 15124692
    [No Abstract]   [Full Text] [Related]  

  • 11. [Phase I study].
    Taguchi T
    Gan To Kagaku Ryoho; 1995 Apr; 22(5):603-6. PubMed ID: 7717710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethical issues in phase I clinical trials.
    Daugherty CK
    Clin Adv Hematol Oncol; 2004 Jun; 2(6):358-60. PubMed ID: 16163205
    [No Abstract]   [Full Text] [Related]  

  • 13. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive design may hasten clinical trials.
    Schmidt C
    J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
    [No Abstract]   [Full Text] [Related]  

  • 15. [Accelerated titration design].
    Minami H
    Gan To Kagaku Ryoho; 2000 Sep; 27(10):1601-7. PubMed ID: 11016010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3 + 3 not equal to (Rolling) 6.
    Hartford C; Volchenboum SL; Cohn SL
    J Clin Oncol; 2008 Jan; 26(2):170-1. PubMed ID: 18182656
    [No Abstract]   [Full Text] [Related]  

  • 17. Patient specific dosing in a cancer phase I clinical trial.
    Babb JS; Rogatko A
    Stat Med; 2001 Jul; 20(14):2079-90. PubMed ID: 11439422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence].
    Kusaba H; Tamura T
    Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A combination phase I/II study--dose escalation plan].
    Yamamoto N
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2267-74. PubMed ID: 11142175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.